Research programme: controlled release therapeutic - Flamel/Pfizer
Latest Information Update: 19 Mar 2012
At a glance
- Originator Wyeth
- Developer Flamel Technologies; Pfizer
- Class Proteins
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified